Sarah Rodriguez to Bevacizumab
This is a "connection" page, showing publications Sarah Rodriguez has written about Bevacizumab.
Connection Strength
2.077
-
Neurodevelopmental Outcomes Comparing Bevacizumab to Laser for Type 1 ROP. Ophthalmic Surg Lasers Imaging Retina. 2019 06 01; 50(6):337-343.
Score: 0.632
-
Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. J AAPOS. 2019 04; 23(2):88.e1-88.e6.
Score: 0.620
-
Smartphone application links severity of retinopathy of prematurity to early motor behavior in a cohort of high-risk preterm infants. J AAPOS. 2023 02; 27(1):12.e1-12.e7.
Score: 0.203
-
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis. J Perinatol. 2021 09; 41(9):2377-2378.
Score: 0.182
-
Late visual outcomes in infants treated with primary bevacizumab for type 1 retinopathy of prematurity. J AAPOS. 2020 06; 24(3):149.e1-149.e5.
Score: 0.169
-
Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant With Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2018 11 01; 49(11):893-896.
Score: 0.152
-
Re: Lepore et al.: Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings (Ophthalmology. 2018;125:218-226). Ophthalmology. 2018 10; 125(10):e70-e71.
Score: 0.075
-
Macular Sequelae Following Exudative Retinal Detachment After Laser Photocoagulation for Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina. 2020 Dec 01; 51(12):698-705.
Score: 0.044